On February 25, the in vitro diagnostic reagent manufacturer Jiangsu Bioperfectus Technologies Co.Ltd(688399) released the performance express for 2021. During the reporting period, the company achieved a total operating revenue of 2864.7348 million yuan, a year-on-year increase of 64.67%; The net profit attributable to the owners of the parent company was 1197409200 yuan, a year-on-year increase of 46.10%.
Jiangsu Bioperfectus Technologies Co.Ltd(688399) said that during the reporting period, although the epidemic situation in China was effectively controlled, there were still sporadic cases and repeated cases in some areas. There was still a strong demand for covid-19 nucleic acid detection reagent. The company continued to be committed to the cause of epidemic prevention and control. In view of the normalization of the epidemic situation, the company has accumulated efficient ability to deal with the new normal of covid-19 epidemic, The sales of covid-19 nucleic acid detection reagent increased significantly, which also led to the significant growth of sales of other covid-19 related products.
In addition, under the condition that the epidemic situation has been effectively controlled, the company has strengthened the R & D, production and sales of HPV, BV and other original products, and the sales range has also increased significantly. The above reasons promote the overall business performance of the company to show a large-scale growth in 2021.
